Efficacy and safety of camostat mesylate in early COVID-19 disease in an ambulatory setting: a randomized placebo-controlled phase II trial
Tobback et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2022.06.054
https://c19early.org/tobback.html